Please login to the form below

Not currently logged in
Email:
Password:

Xolair

This page shows the latest Xolair news and features for those working in and with pharma, biotech and healthcare.

AZ prices severe asthma drug Fasenra below competition

AZ prices severe asthma drug Fasenra below competition

Along with Nucala and Cinqair, severe asthma patients can also be treated with Novartis’older drug Xolair (omalizumab), although that is indicated for allergic asthma and doesn’t specifically address eosinophilic

Latest news

More from news
Approximately 9 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Pharma deals during August 2014 Pharma deals during August 2014

    This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics